Jane Huang - Apr 4, 2023 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
President, CMO
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Apr 4, 2023
Transactions value $
-$81,274
Form type
4
Date filed
4/6/2023, 06:19 PM
Previous filing
Feb 9, 2023
Next filing
Jun 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Options Exercise +37.5K 37.5K Apr 4, 2023 Direct F1
transaction PRLD Common Stock Sale -$81.3K -13.3K -35.41% $6.12 24.2K Apr 6, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Restricted Stock Unit Options Exercise $0 -37.5K -25% $0.00 113K Apr 4, 2023 Common Stock 37.5K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSUs") represents a contingent right to receive one share of Issuer's Common Stock.
F2 Represents the aggregate number of shares sold by the reporting person as a result of a mandatory sale to cover taxes and fees due upon the release and settlement of the RSUs. The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.90 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F4 The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.